Skip to main content
Top
Published in: Medical Oncology 3/2015

01-03-2015 | Original Paper

VGLL4 inhibits EMT in part through suppressing Wnt/β-catenin signaling pathway in gastric cancer

Authors: Hui Li, Ziwei Wang, Wei Zhang, Kun Qian, Gang Liao, Wei Xu, Shouru Zhang

Published in: Medical Oncology | Issue 3/2015

Login to get access

Abstract

VGLL4 is a member of the Vestigial-like proteins that functions as a tumor suppressor, which directly competes with YAP for binding TEADs in several cancer types. Recently, an increasing number of studies have reported that VGLL4 acts as a crucial role in regulating cell mobility, migration, and invasion. However, little is known about the signaling mechanisms in regulating epithelial–mesenchymal transition (EMT) of gastric cancer. In our study, we confirmed that the expression level of VGLL4 was down-regulated in gastric cancer tissues, and reduced VGLL4 expression levels inhibited apoptosis and promoted proliferation, migration, and invasion. Additionally, we found a phenomenon that VGLL4 was associated with the change in nuclear location of β-catenin, which suggested that β-catenin was a significant downstream factor of VGLL4. These results suggest that VGLL4 suppressed EMT in part via negative regulation of Wnt/β-catenin signaling pathway. Taken together, our study demonstrated that VGLL4 is important in the process of suppressing tumor progression of gastric cancer and provided a potential therapeutic strategy for gastric cancer.
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed
3.
go back to reference Fuxe J, Vincent T, de Herreros AG. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle. 2010;9:2363–74.CrossRefPubMed Fuxe J, Vincent T, de Herreros AG. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle. 2010;9:2363–74.CrossRefPubMed
4.
go back to reference Bates RC, Mercurio AM. The epithelial–mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther. 2005;4:365–70.CrossRefPubMed Bates RC, Mercurio AM. The epithelial–mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther. 2005;4:365–70.CrossRefPubMed
5.
go back to reference Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.CrossRefPubMed Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.CrossRefPubMed
6.
go back to reference Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009;139:871–90.CrossRefPubMed Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009;139:871–90.CrossRefPubMed
7.
go back to reference Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.CrossRefPubMed Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.CrossRefPubMed
8.
go back to reference Yang J, Weinberg RA. Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818–29.CrossRefPubMed Yang J, Weinberg RA. Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818–29.CrossRefPubMed
11.
go back to reference Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265–73.CrossRefPubMed Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265–73.CrossRefPubMed
12.
go back to reference Bardeesy N, Cheng KH, Berger JH, Chu GC, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006;20(22):3130–46.PubMedCentralCrossRefPubMed Bardeesy N, Cheng KH, Berger JH, Chu GC, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006;20(22):3130–46.PubMedCentralCrossRefPubMed
13.
go back to reference Wang Z, Li Y, Kong D, Banerjee S, et al. Acquisition of epithelial–mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69(6):2400–7.PubMedCentralCrossRefPubMed Wang Z, Li Y, Kong D, Banerjee S, et al. Acquisition of epithelial–mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69(6):2400–7.PubMedCentralCrossRefPubMed
14.
go back to reference Fu Y, Zheng S, An N, et al. β-catenin as a potential key target for tumor suppression. Int J Cancer. 2011;129(7):1541–51.CrossRefPubMed Fu Y, Zheng S, An N, et al. β-catenin as a potential key target for tumor suppression. Int J Cancer. 2011;129(7):1541–51.CrossRefPubMed
16.
go back to reference Anson M, Crain-Denoyelle AM, Baud V, et al. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest. 2012;122(2):586–99.PubMedCentralCrossRefPubMed Anson M, Crain-Denoyelle AM, Baud V, et al. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest. 2012;122(2):586–99.PubMedCentralCrossRefPubMed
17.
go back to reference Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997;11(24):3286–305.CrossRefPubMed Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997;11(24):3286–305.CrossRefPubMed
18.
19.
go back to reference Chen HH, Mullett SJ, Stewart AF. Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1- adrenergic activation of gene expression in cardiac myocytes. J Biol Chem. 2004;279(29):30800–6.CrossRefPubMed Chen HH, Mullett SJ, Stewart AF. Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1- adrenergic activation of gene expression in cardiac myocytes. J Biol Chem. 2004;279(29):30800–6.CrossRefPubMed
20.
go back to reference Mielcarek M, Gunther S, Kruger M, et al. VITO-1, a novel vestigial related protein is predominantly expressed in the skeletal muscle lineage. Gene Expr Patterns. 2002;2(3–4):305–10.CrossRefPubMed Mielcarek M, Gunther S, Kruger M, et al. VITO-1, a novel vestigial related protein is predominantly expressed in the skeletal muscle lineage. Gene Expr Patterns. 2002;2(3–4):305–10.CrossRefPubMed
21.
go back to reference Mielcarek M, Piotrowska I, Schneider A, et al. VITO-2, a new SID domain protein, is expressed in the myogenic lineage during early mouse embryonic development. Gene Expr Patterns. 2009;9(3):129–37.CrossRefPubMed Mielcarek M, Piotrowska I, Schneider A, et al. VITO-2, a new SID domain protein, is expressed in the myogenic lineage during early mouse embryonic development. Gene Expr Patterns. 2009;9(3):129–37.CrossRefPubMed
22.
go back to reference Pobbati AV, Hong W. Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther. 2012;14(5):390–8.CrossRef Pobbati AV, Hong W. Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther. 2012;14(5):390–8.CrossRef
23.
go back to reference Pobbati AV, Chan SW, Lee I, et al. Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes. Structure. 2012;20(7):1135–40.CrossRefPubMed Pobbati AV, Chan SW, Lee I, et al. Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes. Structure. 2012;20(7):1135–40.CrossRefPubMed
24.
go back to reference Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9(2):121–32.CrossRefPubMed Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9(2):121–32.CrossRefPubMed
25.
go back to reference Helias-Rodzewicz Z, Perot G, Chibon F, et al. YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosom Cancer. 2012;49(12):1161–71.CrossRef Helias-Rodzewicz Z, Perot G, Chibon F, et al. YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosom Cancer. 2012;49(12):1161–71.CrossRef
26.
go back to reference Mann KM, Ward JM, Yew CC, et al. Sleeping beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci USA. 2012;109(16):5934–41.PubMedCentralCrossRefPubMed Mann KM, Ward JM, Yew CC, et al. Sleeping beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci USA. 2012;109(16):5934–41.PubMedCentralCrossRefPubMed
27.
go back to reference Jin HS, Park HS, Shin JH, et al. A novel inhibitor of apoptosis protein (IAP)-interacting protein, Vestigial-like (Vgl)-4, counteracts apoptosis-inhibitory function of IAPs by nuclear sequestration. Biochem Biophys Res Commun. 2012;412(3):454–9.CrossRef Jin HS, Park HS, Shin JH, et al. A novel inhibitor of apoptosis protein (IAP)-interacting protein, Vestigial-like (Vgl)-4, counteracts apoptosis-inhibitory function of IAPs by nuclear sequestration. Biochem Biophys Res Commun. 2012;412(3):454–9.CrossRef
28.
go back to reference Jiao S, Wang H, Shi Z, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014;25(2):166–80.CrossRefPubMed Jiao S, Wang H, Shi Z, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014;25(2):166–80.CrossRefPubMed
29.
30.
go back to reference Xu W, Wang Z, Zhang W et al. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway. Cancer Lett. 2015;356(2 Pt B):613–27.CrossRefPubMed Xu W, Wang Z, Zhang W et al. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway. Cancer Lett. 2015;356(2 Pt B):613–27.CrossRefPubMed
31.
go back to reference Zha L, Zhang J, Tang W, et al. HMGA2 elicits EMT by activating the Wnt/b-catenin pathway in gastric cancer. Dig Dis Sci. 2013;58:724–33.CrossRefPubMed Zha L, Zhang J, Tang W, et al. HMGA2 elicits EMT by activating the Wnt/b-catenin pathway in gastric cancer. Dig Dis Sci. 2013;58:724–33.CrossRefPubMed
32.
go back to reference Zhang W, Gao Y, Li P, et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 2014;24(3):331–43.PubMedCentralCrossRefPubMed Zhang W, Gao Y, Li P, et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 2014;24(3):331–43.PubMedCentralCrossRefPubMed
Metadata
Title
VGLL4 inhibits EMT in part through suppressing Wnt/β-catenin signaling pathway in gastric cancer
Authors
Hui Li
Ziwei Wang
Wei Zhang
Kun Qian
Gang Liao
Wei Xu
Shouru Zhang
Publication date
01-03-2015
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-015-0539-5

Other articles of this Issue 3/2015

Medical Oncology 3/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.